Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383985 | 0.91 | LMNA (0.47) | LMNASMN1; SMN2PKMMAPTKMT2A | |
| SCHEMBL5670152 | 0.78 | CYP1A2 (0.50) | LMNASMN1; SMN2PKMMAPTKMT2A | |
| SCHEMBL5668546 | 0.78 | IGF1R (0.49) | SMN1; SMN2MAPTKMT2APOLBTP53 | |
| SCHEMBL4392420 | 0.77 | CYP1A2 (0.52) | LMNASMN1; SMN2MAPTKMT2APOLB | |
| SCHEMBL12481961 | 0.77 | HTT (0.46) | SMN1; SMN2MAPTKMT2APOLBTP53 | |
| SCHEMBL4387708 | 0.77 | TRPV1 (0.44) | LMNASMN1; SMN2MAPTPOLBTP53 | |
| SCHEMBL2172869 | 0.76 | CYP1A2 (0.43) | SMN1; SMN2MAPTKMT2APOLBALDH1A1 | |
| SCHEMBL11910564 | 0.76 | CYP1A2 (0.68) | LMNASMN1; SMN2PKMMAPTKMT2A | |
| SCHEMBL4397607 | 0.76 | CYP1A2 (0.46) | LMNASMN1; SMN2MAPTKMT2APOLB | |
| SCHEMBL10126403 | 0.75 | IGF1R (0.52) | LMNASMN1; SMN2PKMMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973061-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | LMNA 1626/4885SMN1; SMN2 4564/4885PKM 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.